Close Menu

Looking Into It

A second death in a trial of Novartis' gene therapy, Zolgensma, for type 1 spinal muscular atrophy is under investigation, Reuters reports. Type 1 SMA leads to paralysis and breathing trouble.

Reuters adds that the firm recently reported positive interim trial results and filed for US Food and Drug Administration approval based on a trial of 15 babies given Zolgensma. Reuters notes that a decision is expected within weeks.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.